

## **Biogen releases more positive data for oral MS drug**

Mass High Tech: The Journal of New England Technology

Biogen Idec (NASDAQ: BIIB) is awaiting approval from the U.S. Food and Drug Administration for its first oral multiple sclerosis therapy, and has released new Phase 3 data that shows positive efficacy and safety for the drug candidate. The FDA is scheduled to make a decision on or before Dec. 28.

**Source URL (retrieved on 01/31/2015 - 2:38am):**

<http://www.mdtmag.com/news/2012/10/biogen-releases-more-positive-data-oral-ms-drug>